Author

Amanda Jiang

University of UtahORCID 0000-0002-0327-6980Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Amanda Jiang1 paper

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Genetic & Genomic Medicine· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 3 Assay:bulk RNA-seq· 2 Research Focus:cancer & tumor microenvironment· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:differential expression· 1 Research Focus:gene regulatory network inference· 1

Frequent Co-Authors

Dekker C. DeaconiD· 3 shared Carly A. BeckeriD· 2 shared Emilio Cortes-SancheziD· 2 shared R. L. BeloteiD· 2 shared Richard Mark WhiteiD· 2 shared Robert L. Judson‐TorresiD· 2 shared Alethia Álvarez‐CanoiD· 1 shared Alfredo Hidalgo‐MirandaiD· 1 shared

Activity by Year

2024-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 37 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

Dekker C. DeaconORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Genetic Drivers of Sensitivity or Resistance to RAS(ON) Multi-Selective Inhibitors in NRAS-Mutated Melanoma

Mona Foth, Wontak Kim, Kayla T. O’Toole, Brandon Murphy, Montserrat Justo-Garrido, Sanjana Srinivas Boggaram, Phaedra C. Ghazi, Euan Brennan, M. Isaac Wright, Tate Shepherd, Emilio Cortes-Sanchez, Yingyun Wang, Jennifer A. Roth, Matthew G. Rees, Melissa M. Ronan, , Martin McMahon

This study identifies RAS(ON) inhibitors effective against NRAS-mutated melanoma and reveals resistance mechanisms through Ppia and Map2k1 mutations.

Cancer Research · May 22, 2026Peer-reviewedCancer Biology

Receptor tyrosine kinase inhibition leads to regression of acral melanoma by targeting the tumor microenvironment

Eric A. Smith, R. L. Belote, Nelly M. Cruz, Tarek E. Moustafa, Carly A. Becker, Amanda Jiang, Shukran Alizada, Anastasia Prokofyeva, Tsz Yin Chan, Tori A. Seasor, Michael A. Balatico, Emilio Cortes-Sanchez, David Henry Lum, John Robert Hyngstrom, Hanlin Zeng, , Robert L. Judson‐Torres

This study shows that dual FGFR/VEGFR inhibition causes regression of acral melanoma by targeting the tumor microenvironment rather than directly killing cancer cells.

Journal of Experimental & Clinical Cancer Research · Dec 3, 2024Peer-reviewedCancer Biology

Ancestry and somatic profile predict acral melanoma origin and prognosis

Patricia Basurto‐Lozada, Martha Estefania Vázquez‐Cruz, Christian Molina‐Aguilar, Amanda Jiang, Dekker C. Deacon, Dennis Cerrato-Izaguirre, Irving Simonin Wilmer, Fernanda Guadalupe Arriaga-González, Kenya L. Contreras-Ramírez, Emiliano Ferro-Rodríguez, Jamie Billington, Eric T. Dawson, J. Rene C. Wong-Ramirez, Johana Itzel Ramos-Galguera, Alethia Álvarez‐Cano, , Carla Daniela Robles‐Espinoza

This study analyzes acral melanoma genomes and transcriptomes from Mexican patients, finding ancestry-related mutation patterns and survival differences.

medRxiv · Sep 21, 2024 · PreprintGenetic & Genomic Medicine